Semler Scientific Investor Presentation — August 2022

Document content

August 2022Forward -Looking Statements

This presentation includes statements that are, or may be deemed, “forward -looking statements.” In some cases, these forward -looking statements can be

identified by the use of forward -looking terminology, including the terms “believe,” “estimate,” “anticipate,” “expect,” “plan,” “intend,” “may,” “could ,” “might,”

“will,” “should,” or, in each case, their negative or other variations thereon or comparable terminology, although not all forwa rd-looking statements contain these

words. Such forward -looking statements appear in a number of places throughout this presentation and include statements regarding QuantaFlo® aiding in

diagnosis of other cardiovascular diseases, ourup to $20.0 million buyback program and any purchases thereunder, our expectations regarding new products and

service offerings, our expected range of revenues and operating expenses for the second half and full year of 2022, as well a s statements regarding our goals for

the year, among others. These statements are based on our current intentions, beliefs, projections, outlook, analyses or cu rrent expectations concerning, among

other things, the impact of healthcare reform (including the Affordable Care Act) on our business, the effect of new financia l incentives for medical providers and the

amount of such payments, our ongoing and planned development of products, the timing of launch of such new products, the stre ngth and breadth of our

intellectual property, the degree of clinical utility and adoption of our product, particularly for specific patient populati ons, and the success of new service models.

By their nature, forward -looking statements involve risks and uncertainties because they relate to events, competitive dynamics, our expected financing needs and